A prospective study to examine the effectiveness and safety of neuraminidase inhibitors in index cases with presumed pandemic influenza infectio
Not Applicable
- Conditions
- Pandemic influenzaInfection - Other infectious diseases
- Registration Number
- ACTRN12608000176369
- Lead Sponsor
- ational Centre in HIV Epidemiology and Clinical Research (NCHECR)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
1. Clinical diagnosis of pandemic influenza (consistent with the applicable clinical case definition)
2. Provision of written informed consent or equivalent
3. Intention to commence treatment with a neuraminidase inhibitor
Exclusion Criteria
There are no exclusion criteria.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie neuraminidase inhibitor efficacy in pandemic influenza viral replication?
How do neuraminidase inhibitors compare to standard-of-care antivirals in pandemic influenza treatment outcomes?
Which biomarkers correlate with response to neuraminidase inhibitors in ACTRN12608000176369 influenza studies?
What adverse events are associated with neuraminidase inhibitor use in ACTRN12608000176369 pandemic influenza cases?
Are there combination therapies or alternative antiviral agents that enhance neuraminidase inhibitor effectiveness in pandemic influenza?